The Corporate Advisory Team
PharmaVentures' Corporate Advisory team has a broad range of experiences covering multiple sectors of the pharmaceutical and biotechnology industries.
Adrian Dawkes, PhD (Senior Director)
Adrian has significant multi-discipline expertise spanning research & development through to sales, marketing and business development from 25 years in the pharmaceutical, biotechnology and in vitro diagnostics sectors. Adrian has held senior positions with Johnson & Johnson, drug discovery platform company Acumen Bioscience and the Healthcare Consultancy company Execute Technologies. Adrian has a BSc in Biochemistry and a PhD in Immunochemistry from Oxford Brookes.
Watch Adrian on PharmaTelevision
Kate Moore, PhD (Director)
Kate has 15 years of experience in the biotechnology industry, most recently as Director of Business Development at TopoTarget. Kate has a successful track record in negotiating in- and out- licensing deals, conducting market evaluations and technical and commercial due diligence. Kate has also held positions in marketing and research at BD Biosciences, BioCarta and Prolifix. Kate has an undergraduate degree from Oxford University and a PhD in Molecular Biology from University College London.
Watch Kate on PharmaTelevision
Nick Hyde M.A., C. Dip. A.F. (Associate Principal)
Prior to joining with PharmaVentures in 2008 Nick was business leader for Dowpharma and was a key member of the team which successfully divested this business. He is a graduate in engineering from Cambridge University, UK, and has worked for a total of 24 years for ICI, Zeneca, AstraZeneca and Avecia in a range of roles in manufacturing and business management, culminating in having responsibility for more than 400 staff across four sites in the UK. He was Vice President of Avecia’s Pharmaceutical Services business from 2000 to 2002. Nick joined Dow Chemical in September 2002 and led the consolidation of all Dow Chemical service and technology offerings to the pharmaceuticals industry and the subsequent rationalisation program. Nick’s industry leadership was recognised by his election to the Board of Governors of the US trade organisation, SOCMA, in 2001 and 2002.
Robert V Fishleigh, B.A. (Cantab), Ph.D. (Associate Director)
Bob has served as a consultant to pharmaceutical, biotechnology and other healthcare companies for over ten years and, in that time, has worked on some 150 assignments in the areas of strategy and business planning; technical evaluation; market assessment; valuation; due diligence and Experts. reports; licensing/partnering; and litigation support. Before entering consultancy, Bob was a member of the founding entrepreneurial team of Proteus International plc (now BTG plc). During his ten years at Proteus, Bob held various R&D and commercial positions and served as a Director of Progene Partners, a joint venture with Genelabs Technologies, Inc.